B. Riley Financial Varied
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Tela Bio Inc (NQ: TELA )

4.250 -0.120 (-2.75%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 110,208
Open 4.310
Bid (Size) 4.040 (4)
Ask (Size) 5.420 (1)
Prev. Close 4.370
Today's Range 4.145 - 4.390
52wk Range 4.030 - 9.940
Shares Outstanding 24,655,371
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
TELA Bio to Participate in the Canaccord Genuity 44th Annual Growth Conference
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio to Announce Second Quarter 2024 Financial Results
From TELA Bio, Inc.
Via GlobeNewswire

Performance

YTD
-35.80%
-35.80%
1 Month
-2.30%
-2.30%
3 Month
-9.96%
-9.96%
6 Month
-38.76%
-38.76%
1 Year
-56.10%
-56.10%

More News

Read More
TELA Bio Appoints Jeffrey Blizard to its Board of Directors
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio Appoints Greg Firestone as Chief Commercial Officer
From TELA Bio, Inc.
Via GlobeNewswire
Recap: TELA Bio Q4 Earnings
Via Benzinga
Preview: TELA Bio's Earnings
Via Benzinga
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From TELA Bio, Inc.
Via GlobeNewswire
TELA Stock Earnings: TELA Bio Misses EPS, Beats Revenue for Q1 2024
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
TELA Bio Reports First Quarter 2024 Financial Results
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio to Announce First Quarter 2024 Financial Results
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio Announces U.S. Commercial Launch of Robotic-Compatible OviTex® IHR – Addressing the Need for a More Natural Repair in Inguinal Hernia Procedures
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio Welcomes Acclaimed Surgeon as Vice President of Medical Affairs and Surgeon Strategy
From TELA Bio, Inc.
Via GlobeNewswire
TELA Stock Earnings: TELA Bio Misses EPS, Beats Revenue for Q4 2023
Via InvestorPlace
TELA Bio Announces U.S. Commercial Launch of LIQUIFIX™ – the Only FDA-Approved Liquid Adhesive for Internal Use in Hernia Surgery
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio Announces Sale of Distribution Rights for Wound Care Product to MIMEDX
From TELA Bio, Inc.
Via GlobeNewswire
Earnings Scheduled For March 21, 2024
Via Benzinga
TELA Bio to Announce Fourth Quarter and Full Year 2023 Financial Results
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio to Take Part in Connecting the Dots
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio to Participate in Piper Sandler’s 35th Annual Healthcare Conference
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From TELA Bio, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
B. Riley Financial's diverse suite of services goes beyond traditional financial service offerings. By leveraging cross-platform expertise and assets, B. Riley Financial companies are uniquely positioned to provide full service, collaborative solutions to our clients at every stage of the business life cycle and in all market conditions.

B. Riley refers to B. Riley Financial, Inc. and/or one or more of its subsidiaries or affiliates. Click here for further details.